| Prohealth Primary Care Llc | |
|
115 W Bel Air Ave Aberdeen MD 21001-3221 | |
| (410) 272-3377 | |
| (410) 273-1479 |
| Full Name | Prohealth Primary Care Llc |
|---|---|
| Speciality | Pediatrics |
| Location | 115 W Bel Air Ave, Aberdeen, Maryland |
| Authorized Official Name and Position | Nathaniel Sumilang (PHYSICIAN/OWNER) |
| Authorized Official Contact | 4102723377 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Prohealth Primary Care Llc 115 W Bel Air Ave Aberdeen MD 21001-3221 Ph: (410) 272-3377 | Prohealth Primary Care Llc 115 W Bel Air Ave Aberdeen MD 21001-3221 Ph: (410) 272-3377 |
| NPI Number | 1982962692 |
|---|---|
| Provider Enumeration Date | 05/01/2012 |
| Last Update Date | 05/01/2012 |
| Medicare PECOS PAC ID | 7214183227 |
|---|---|
| Medicare Enrollment ID | O20120807000661 |
News Archive
The disparity in vaccination rates across England is investigated based on demographic variables, finding significant differences based on ethnicity and religion.
Women who have hypertensive complications during pregnancy are at increased risk for developing chronic kidney disease and end-stage renal disease, shows a study in the Canadian Medical Association Journal.
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.
A type of artificial intelligence called machine learning can help predict which patients will develop diabetes, according to an ENDO 2020 abstract that will be published in a special supplemental section of the Journal of the Endocrine Society.
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982962692 | NPI | - | NPPES |
| 402019701 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | M38486 (Maryland) | Secondary |
| 208000000X | Pediatrics | D0059126 (Maryland) | Primary |
| Provider Name | Gwenneth O Cancino |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487657227 PECOS PAC ID: 3072412188 Enrollment ID: I20101122000020 |
News Archive
The disparity in vaccination rates across England is investigated based on demographic variables, finding significant differences based on ethnicity and religion.
Women who have hypertensive complications during pregnancy are at increased risk for developing chronic kidney disease and end-stage renal disease, shows a study in the Canadian Medical Association Journal.
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.
A type of artificial intelligence called machine learning can help predict which patients will develop diabetes, according to an ENDO 2020 abstract that will be published in a special supplemental section of the Journal of the Endocrine Society.
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
› Verified 3 days ago
| Provider Name | Nathaniel M Sumilang |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1932192754 PECOS PAC ID: 4486800497 Enrollment ID: I20120807000687 |
News Archive
The disparity in vaccination rates across England is investigated based on demographic variables, finding significant differences based on ethnicity and religion.
Women who have hypertensive complications during pregnancy are at increased risk for developing chronic kidney disease and end-stage renal disease, shows a study in the Canadian Medical Association Journal.
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.
A type of artificial intelligence called machine learning can help predict which patients will develop diabetes, according to an ENDO 2020 abstract that will be published in a special supplemental section of the Journal of the Endocrine Society.
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
› Verified 3 days ago
| Provider Name | Christopher James Cancino |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1316326846 PECOS PAC ID: 4688024714 Enrollment ID: I20240102001243 |
News Archive
The disparity in vaccination rates across England is investigated based on demographic variables, finding significant differences based on ethnicity and religion.
Women who have hypertensive complications during pregnancy are at increased risk for developing chronic kidney disease and end-stage renal disease, shows a study in the Canadian Medical Association Journal.
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.
A type of artificial intelligence called machine learning can help predict which patients will develop diabetes, according to an ENDO 2020 abstract that will be published in a special supplemental section of the Journal of the Endocrine Society.
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
› Verified 3 days ago
News Archive
The disparity in vaccination rates across England is investigated based on demographic variables, finding significant differences based on ethnicity and religion.
Women who have hypertensive complications during pregnancy are at increased risk for developing chronic kidney disease and end-stage renal disease, shows a study in the Canadian Medical Association Journal.
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.
A type of artificial intelligence called machine learning can help predict which patients will develop diabetes, according to an ENDO 2020 abstract that will be published in a special supplemental section of the Journal of the Endocrine Society.
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
› Verified 3 days ago
Belair Primary Care, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 19 Walnut Ln, Aberdeen, MD 21001 Phone: 410-272-3233 | |
Medstar Orthopaedic Institute At Aberdeen Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 998 Hospitality Way Ste 101, Aberdeen, MD 21001 Phone: 410-638-9001 | |
Patient First - Aberdeen Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 995 Hospitality Way, Aberdeen, MD 21001 Phone: 410-306-7880 | |
Upper Chesapeake Primary Care,llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 650 Mchenry Rd Ste 3200, Aberdeen, MD 21001 Phone: 443-843-6262 Fax: 443-843-6264 | |
Agnes Health Quick Care Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 219 W Bel Air Ave, Suite 2, Aberdeen, MD 21001 Phone: 410-272-7474 Fax: 410-272-7442 | |
Bayside Internal Medicine Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 998 Hospitality Way, Suite 102, Bayside Internal Medicine, Llc, Aberdeen, MD 21001 Phone: 410-297-9500 Fax: 410-297-9016 | |
Hchd Swan Creek School-1407975964 Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 253 Paradise Rd, Aberdeen, MD 21001 Phone: 410-877-1033 Fax: 410-420-3435 |